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Poster Session II S335HSCT exhibited a significantly better survival than recipients of D1
SH or D2 SH transplants. However, after a low dose T cell infusion
(1 x105), recipients of D2 BM survived significantly better than recip-
ients of D1BM. In contrast to theTCDmodel, recipients ofDHBM
+ DH T cells show similar probability of survival with recipients of
D2 SH BM + D2 SH T. These data suggest that T cells from
B6SJLF1 have less anti-tumor activity than B6CBAF1 T cells.
We conclude that TCD DH HSCT results in successful engraft-
ment of both types of BM cells. Additionally, infusion of low dose
haploidentical T cells improves the anti-tumor effect without
stimulating GVHD. Double haploidentical HSCT may be an ideal
platform to enhance GVL effects after transplantation.506
WHOLE GENOME ANALYSIS OF CANDIDATE MINOR HISTOCOMPATIBIL-
ITY ANTIGENS PREDICTS A SMALL NUMBER OF COMMON, TIGHT-BIND-
ING EPITOPES TO HLA-A AND B SUPERTYPES
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Minor histocompatibility antigens (mHAs) mediate much of the
graft vs. leukemia (GvL) effect and graft vs. host disease (GvHD).
Immune responses to mHAs often result from disparities between
donor and recipient non-synonymous, coding, single-nucleotide
polymorphisms (cSNPs). Using high density DNA microarrays,
we associated genetic predictors of an mHA response (gIR) with ev-
idence of a clinical immune response (cIR), GvHD and or long-term
remission, and identified a novel, common mHA, T4A. Because of
multiple testing of large numbers of cSNPs and the statistical power
limitations caused by a relatively small number of SCT patients in
the cSNP analysis, we observed a high false positive prediction rate
with 40 cSNPs being screened to yield T4A. The purpose of our cur-
rent work is to develop a bioinformatics pipeline to identify all of the
cSNPs that could yield common mHAs from a large genomics
dataset, therebyminimizing the sample size and statistical limitations
encountered by high density DNA microarray methodologies.
We downloaded all cSNPs with a minor allele frequency $ 0.1
from CEU population of The HapMap Genome Browser Release-
27 and selected the alleles with a predicted minor mismatch
probability P(gIR)$ 0.16. The cSNPs were mapped to their known
flanking amino-acid sequences and were analyzed using the IEDB
ANN algorithm for binding to class I HLA supertypes using a cutoff
IC50\ 200 nM.
Of the 11,887 alleles evaluated, 2,240 encoded a peptide that could
be presented in at least 1HLA-A supertype, and 1,811 encoded a pep-
tide that could be presented in at least 1 HLA-B supertype. Many of
the examined alleles encoded peptides that could be presented by
several HLA supertypes, resulting in a total of 5,053 HLA-A super-
type epitopes and 3,060 HLA-B supertype epitopes being predicted.
We tested our method’s predictive ability by measuring binding of
92 of the predicted HLA-A02 supertype epitopes to HLA-A0201
using the iTopia Epitope Discovery System. Ninety percent of our
predicted epitopes bound to HLA-A0201 using this assay. Most epi-
topes predicted to have an IC50\50 nM had an HLA-dissociation
t1/2 . 8 hours (P0.0170).
Out of the 4,030,560 cSNPs in the HapMap set, our method pre-
dicted a relatively small number of epitopes that are likely to have
strong binding affinity to HLA molecules. By applying this method
to a large patient cohort the chances of identifying common, clini-
cally significant mHAs should be greatly enhanced.507
INCREASED PRODUCTION OF THE INFLAMMATORY CYTOKINE IL12P70
BY ACTIVATED HUMAN BLOOD DENDRITIC CELLS IS ASSOCIATED
WITH INCREASED SEVERITY OF ACUTE GRAFT VS HOST DISEASE POST
ALLOGENEIC STEM CELL TRANSPLANTATION
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Introduction: The activation status of peripheral blood CD11c+
myeloid dendritic cells (DC) as assessed by CMRF-44 antigen ex-pression is highly associated with the severity of acute GvHD
(Transplantation 2007;83: 839–846). However, very little is known
about the function of post transplantDC.We examined the relation-
ship between DC functional properties and the severity of acute
GvHD.
Method: Peripheral blood CD11c+ myeloid DC from 12 patients
were studied weekly up to 8 weeks post transplant for production
of IL2, IL4, INFg, IL10 and IL12 using an intracellular cytokine
flow assay. Mixed lymphocyte reactions were used to assess alloge-
neic immune responses in 5 patients.
Results: IL12 was the only cytokine detected in post transplant
DC. Five of 12 patients developed moderate to severe aGvHD
(grade II-IV), the remaining 7 patients developed either no
aGvHD or only grade I. In comparison with pre-transplant
levels of expression, patients with grade 11-1V had up to 4
fold higher percentage of CD11c+ DC expressing IL12 (median
15.1%, range 11.2-20.9%) as compared to patients with grade
0-1 aGvHD in whom there was no change from baseline values
(median 6.6% range 2.8-8.9%) p 5 0.0025. Increased expression
of IL12 was observed in CD11c+ DC commencing at day 25
post transplant. Interestingly, analysis of paired samples from
5 patients comparing sorted DC from donors with sorted DC
from peripheral blood of transplant patients at day +30 post-
transplant showed a marked reduction in the capacity of
post-transplant donor DCs to stimulate 3rd party lymphocyte
proliferation. None of these patients developed clinically signif-
icant aGvHD.
Conclusion: production of IL-12p70 by CD11c+ myeloid
DC correlates with severity of GvHD despite apparent defects
in the capacity of these cells to elicit 3rd party proliferative
responses.508
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Minor histocompatibility antigens (mHags) are the molecular
targets of allo-immunity responsible both for the development
of antitumor effects and for graft-versus-host disease (GVHD)
in allogeneic hematopoietic stem cell transplantation (allo-
HSCT). Recently, we have reported that the large data set from
the International HapMap Project can be directly used for genetic
mapping of novel mHags when combined with conventional
immunologic assays such as interferon-gamma enzyme linked
immunosorbent assay (ELISA) or chromium release assay. The
target mHag locus can be uniquely mapped through whole ge-
nome association scanning based on immunologically-determined
mHag status in HapMap Epstein Barr virus-transformed (EBV)-
LCL panels transduced with retroviruses encoding predetermined
restriction HLA allele cDNAs. Once stably transduced, they are
easily maintained or cryopreserved for future use as screening
panels.
We have constructed an online interactive program to search
for single nucleotide polymorphisms (SNPs) responsible for not
only mHag generation but also specific cell phenotypes (e.g. sen-
sitivity or resistance to given drugs) by simply selecting ‘‘pheno-
type-positive’’ or ‘‘phenotype-negative’’ in a pull-down menu for
individual HapMap EBV-LCLs shown in the entry page. Three
data sets from CEU, JPT and CHB will be ready for use. A list
of candidate SNPs will be shown in a new page. The website
will be available as ‘‘HapMap Scanner’’ in the near future.
Thus, once suitable assays are generated, this method should
substantially facilitate discovery of novel SNPs applicable to
identifying patients who can benefit from SNP-based customized
therapies.
